Business
TikTok-fueled K-beauty boom triggers a retail race in the U.S.
Carly Xie looks over facial mask items at the Face Shop, which specializes in Korean cosmetics, in San Francisco, April 15, 2015.
Avila Gonzalez | San Francisco Chronicle | Hearst Newspapers | Getty Images
On a recent Saturday at an Ulta Beauty store in midtown Manhattan, Denise McCarthy, a mother in her 40s, stood in front of a wall of tiny pastel bottles, tubes and compacts. Her phone buzzed — another TikTok from her 15-year-old daughter.
“My kids text me the TikToks,” she told CNBC, scooping Korean lip tints and sunscreens into her basket, destined for Christmas stockings. “I don’t even know what half of this does. I just buy the ones they send me.”
Two aisles over, a group of college students compared swatches of Korean cushion foundations. A dad asked a store associate whether a viral Korean sunscreen was the one “from the girl who does the ‘get ready with me’ videos.” Near the checkout, a display of Korean sheet mask mini-packs was nearly empty.
Scenes like this are playing out across the country.
Once a niche reserved for beauty obsessives, Korean cosmetics — known as K-beauty — are breaking fully into the American mainstream, fueled by TikTok virality, younger and more diverse shoppers, and aggressive expansion from retailers such as Ulta, Sephora, Walmart and Costco.
K-beauty sales in the United States are expected to top $2 billion in 2025, up more than 37% from last year, according to market research firm NielsenIQ, far outpacing the broader beauty market’s single-digit growth.
And even as trade tensions complicate supply chains, brands and retailers told CNBC the momentum is strong.
“We have no plans of slowing down and see more opportunities to penetrate the market,” said Janet Kim, vice president at K-beauty brand Neogen.
In the first half of 2025, South Korea shipped a record $5.5 billion worth of cosmetics, up nearly 15% year over year, and has become the leading exporter of cosmetics to the U.S., surpassing France, according to data from the South Korean government.
“The growth has been remarkable,” said Therese-Ann D’Ambrosia, vice president of beauty and personal care at NielsenIQ. “When you compare that to the broader beauty market, which is growing at single digits, K-beauty is clearly operating in a different gear right now.”
Facial skin care remains the biggest K-beauty revenue driver in the U.S., NielsenIQ reported. Hair care is growing fastest, and hybrid items such as tinted serums and skin care-infused cushion compacts — sponge cushions soaked with an SPF foundation — continue to surge, the firm said.
Big business
Retailers are racing to take advantage of the cosmetics boom, and a turf war is underway.
Ulta, which has over 1,400 U.S. stores, launched “K-beauty World” in July, to spotlight Korean brands and tech devices. It’s the only major U.S. retailer carrying products from Medicube, a beauty-tech company touted by celebrities such as Hailey Bieber.
Ulta’s first quarter 2025 report cited a 38% increase in Korean skin care sales, and executives said in August that new K-beauty partnerships contributed to the company beating Wall Street expectations for earnings in the second quarter.
Sephora is leaning in as well. Its Times Square flagship location now features an entire wall of Korean skin care and cosmetics, and the retailer secured exclusive U.S. launches for Korean heritage brand Hanyul and sensitive-skin label Aestura.
Big-box players are piling in too. Costco and Walmart have also expanded their assortments, adding essences, serums and sheet masks as demand accelerates.
“It’s an arms race to see who can capitalize on the market for Korean products,” Delphine Horvath, professor of cosmetics and fragrance marketing at the Fashion Institute of Technology, told CNBC. “These products are now seen as a top driver of growth for cosmetic brands, and it seems it will keep booming.”
The competition is heating up just as Olive Young, often called the “Sephora of Seoul,” prepares to open its first U.S. store in Los Angeles next year. Asian beauty retailer Sukoshi is also expanding, planning 20 new stores in the coming year across cities such as Seattle, Miami, and Austin, Texas.
“Meeting customers where they can touch, feel and try what they see on TikTok is key,” Sukoshi CEO Linda Dang told CNBC. “Across the industry, companies are looking to expand partly because people really don’t want to have to wait for shipping or travel all the way to Korea to get products.”
The boom arrives in the middle of the ongoing trade war.
This spring, U.S. shoppers rushed to stock up on K-beauty favorites, bracing for price hikes from tariffs, Dang said. However, prices ultimately stayed relatively stable as Korean brands have temporarily absorbed the duties, Dang said, though many are now exploring alternative manufacturing or shipping methods.
South Korea finalized a deal with President Donald Trump last month, settling on a 15% tariff rate instead of the initial 25% levy the president announced in April.
“The system of easy trading isn’t what it was before tariffs,” Dang told CNBC. “That being said, a lot of companies have worked with advertisers and internally to do their best to offset and prevent passing those costs on to customers in the U.S.”
A visitor tries Korean-made cosmetics during the 2022 Korea Tourism Organization’s Discover Your Korea, in Vanderbilt Hall of Grand Central Terminal, New York.
Lev Radin | Pacific Press | Lightrocket | Getty Images
The ‘second wave’
Over the past decade, there’s also been a rise in Korean entertainment in the U.S. — from pop groups such as BTS and Blackpink to this year’s Netflix hit “KPop Demon Hunters” —which has helped push South Korea’s cultural exports to unprecedented popularity.
“Korean culture has exploded on every front, and that has really shown up when it comes to K-beauty,” Dang said.
K-beauty’s “first wave,” which hit the U.S. in the mid-2010s, was defined by “glass skin,” 10-step routines, snail mucin, cushion compacts and beauty blemish creams. Most products catered to lighter skin tones, and distribution was limited to small boutiques, Amazon sellers and early test placements at Ulta and Sephora, beauty experts said.
“The first wave had some penetration, but nothing like today,” Horvath said. “It was mostly people in the know.”
The second wave has been bigger, faster and far more inclusive. It has spanned color cosmetics, hair and scalp care, body care, fragrances and high-tech devices.
TikTok is the central engine of discovery, especially for Gen Z and millennial shoppers, who account for roughly three-fourths of K-beauty consumers, according to a Personal Care Insights market analyst report. Posts tagged “K-beauty” or “Korean skin care” draw 250 million views per week, according to consumer data firm Spate. And viral products with sleek packaging often vanish from shelves faster than retailers can restock — particularly those that combine gentle formulas and low prices, Dang said.
“TikTok has changed the game,” Horvath said. “It’s easier to educate consumers on innovation and get the word out. Brands are deeply invested in paying influencers, and TikTokers talk about textures, formulas and efficacy.”
Virality has also pushed brands to be more inclusive for younger and more diverse shoppers. After TikTok creators criticized Korean brand Tirtir for offering only three foundation shades, the company expanded to 40 shades within months and many other companies followed suit.
The trend is visible across the Americas: 61% of consumers in Mexico and nearly half in Brazil say K-beauty is popular in their country, compared with about 45% in the U.S., according to Statista.
“Traditional retail and e-commerce remain important, but TikTok Shop is the standout disruptor,” said Nielsen’s D’Ambrosia. “It’s not just about the direct sales on that one platform; it’s about how it’s changing the entire discovery and purchase journey.”
But the second wave brings its own risks. A heavy dependence on virality could expose brands to sudden algorithm changes or regulatory scrutiny, D’Ambrosia said.
“When you have so much growth concentrated on one platform [such as TikTok], algorithm changes could significantly impact discoverability overnight,” D’Ambrosia said. “We’ve seen what happens when platforms tweak their recommendation engines. … There are definitely some caution flags we’re watching.”
Collagen eye patches and face masks at the Face Shop, which specializes in Korean beauty items, in San Francisco, April 15, 2015.
Avila Gonzalez | San Francisco Chronicle | Hearst Newspapers | Getty Images
Rapid innovation
K-beauty’s staying power, Dang said, is rooted in an intensely competitive domestic Korean market. Trends move at breakneck speed and consumers spend more per capita on beauty than in any other country, according to South Korean research firm KOISRA.
South Korea had more than 28,000 licensed cosmetics sellers in 2024 — nearly double that of five years ago — creating a pressure-cooker environment that forces constant experimentation, said Neogen’s Kim.
“We develop about hundreds of formulas each day,” Kim told CNBC. “We build the library and we test results with clinical individual tests. … Everything that’s very unique and works really well for skin care, we develop.”
Korean consumers churn through trends quickly, fueling a pipeline of upstart brands that can go viral and, in some cases, get acquired. For example, when gooey snail mucin, a gel used to protect and repair people’s skin, took off globally, skin care brand Amorepacific acquired COSRX, the small Korean brand that helped popularize the ingredient, for roughly $700 million.
The next wave of products, analysts predict, are likely to be even more experimental.
Brands are betting on buzzy ingredients such as DNA extracted from salmon or trout sperm that early research suggests may help calm or repair skin. They are also expanding into biotechnology.
“K-beauty is very data-driven. [Artificial intelligence] helps us get fast results for content, formula development, and advertising,” Kim said. “In Korea, they started talking about delivery systems. They’re very good with biotechnology.”
Business
Netflix co-founder Reed Hastings to step down as chairman
Hastings set up the company in 1997, when it rented DVDs to customers and delivered by post.
Source link
Business
Trump nominates Erica Schwartz as CDC director amid turmoil around leadership, vaccine policy
Rear Admiral Erica G. Schwartz.
U.S. Department of Health and Human Services
President Donald Trump on Thursday nominated Erica Schwartz to serve as director of the Centers for Disease Control and Prevention, concluding a monthslong effort to choose a permanent leader of the embattled health agency.
Schwartz, who will have to be confirmed by the Senate, would take over the role as Health and Human Services Secretary Robert F. Kennedy Jr. oversees a string of controversial health policy changes at the agency, including an overhaul of childhood vaccine recommendations.
Schwartz served as deputy surgeon general during the first Trump administration, where she played a major role in the U.S. response to the Covid-19 pandemic. She spent more than 20 year in uniform, including as rear admiral and chief medical officer of the Coast Guard.
Dr. Jay Bhattacharya had been acting director of the CDC — a title that expired last month under federal law. That law, called the Vacancies Act, limits the amount of time an acting officer can serve in place of a Senate-confirmed official to 210 days.
Late last month marked 210 days since the most recent CDC director, Dr. Susan Monarez, was fired.
A sign sits outside of the Centers for Disease Control and Prevention (CDC) Roybal campus in Atlanta, Georgia, U.S. March 18, 2026.
Megan Varner | Reuters
She has so far been the only person to serve as a confirmed CDC director during Trump’s second term, holding the role for under a month last summer. In congressional testimony in September, Monarez said she was fired after refusing Kennedy’s demands to approve vaccine recommendations she believed lacked scientific support.
It is unclear how Schwartz’s views on vaccines or other key public health policies compare with Kennedy’s.
Also on Thursday, Trump said he chose Sean Slovenski as deputy CDC director and chief operating officer, and Jennifer Shuford as deputy CDC director and chief medical officer. Shuford, as head of the Texas Department of State Health Services, led the state’s response to a massive measles outbreak last year, and credited vaccination and testing in declaring it over.
Schwartz’s nomination comes after a tumultuous several months for the agency, which is reeling from the leadership upheaval, plummeting morale, significant staff turnover and controversial changes to U.S. vaccine policy. Ahead of leadership departures last year, staff members were shaken by a gunman’s attack on the CDC’s Atlanta headquarters on Aug. 8.
Last month, a judge blocked a critical vaccine panel’s efforts to overhaul U.S. immunization policy. That includes an effort to reduce the number of recommended childhood shots from 17 to 11.
Trust in federal health agencies has plummeted during Kennedy’s tenure as Health and Human Services secretary, according to a February poll from health policy research group KFF, with declines across the political spectrum.
Business
RFK Jr.’s peptide policy could boost Hims & Hers as its GLP-1 business evolves
Piotr Swat | Lightrocket | Getty Images
As its high-margin compounded GLP-1 business evolves, Hims & Hers Health may be finding a new opportunity in peptides.
Shares of the telehealth company jumped Thursday after HHS Secretary Robert F. Kennedy Jr. announced Wednesday that the FDA plans to convene a Pharmacy Compounding Advisory Committee meeting to review peptides for potential inclusion on the 503A bulk list, a designation that allows drugs to be compounded on an individual prescribed basis rather than mass producing.
For Hims, the bigger story is how expanding compounding for peptides could unlock new revenue streams as it directs members toward branded rather than more profitable compounded GLP-1 drugs. The telehealth company has been building toward a peptide business for years.
Peptides are short chains of amino acids — think of them as small building blocks of proteins — that are being explored for a wide range of health and wellness uses. They’re controversial because scientific evidence on their long-term safety and effectiveness is limited, and their production remains largely unregulated.
Hims & Hers made a significant move into the space in February 2025 when it acquired a California-based peptide facility. At the time, CEO Andrew Dudum called peptide demand “future-facing innovation.”
“Many use cases have yet to be launched,” said Dudum. “Peptide innovation is at the forefront of so many categories we’re excited to start offering.”
Following Kennedy’s announcement on Wednesday, Hims Chief Medical Officer Dr. Patrick Carroll applauded the news as a move away from the “gray market,” saying the goal is to bring peptide therapy into regulated, physician-led care.
“Our medical team believes certain peptide therapies hold meaningful potential in helping Americans live healthier lives, and we are actively exploring how to expand access in a way that will be aligned with FDA guidance,” Carroll said.
Leerink Partners called the news that the FDA will review peptides for the compounding list a positive outcome that could give Hims a clearer regulatory path to scale peptide therapies. Even so, the firm said it will take time for peptides to boost the company’s bottom line.
“This would not immediately translate into revenue, but would seemingly be a growth avenue that HIMS would push hard on,” said Leerink analyst Michael Cherny, who has a hold-equivalent rating on the stock and a $25 price target. It was trading around $26 a share Thursday.
For now the opportunity is still early, and clinical evidence supporting many peptide therapies is still limited.
Of the dozen peptides listed by Kennedy for consideration on the compounding bulk list, one — MK-677 — is often treated as an illegal drug when sold for human consumption. The growth hormone has also been banned by the World Anti-Doping Agency.
Other peptides on the list, such as GHK-Cu and Semax, which are used for cosmetic or cognitive enhancement, are generally viewed as less controversial, but still lack robust scientific backing.
Kennedy — who has supported many medical treatments and food options outside of those backed by mainstream science — was asked about his plans for expanding peptide therapies during a House Ways and Means Committee hearing Thursday.
“Peptides were not supposed to be regulated,” Kennedy said, arguing the Biden administration restricted the use of peptides due to safety concerns that he considers unfounded.
The FDA process is just beginning, and the July meeting will be advisory only, so change is not expected to be immediate.
Even so, investors are already focusing on what replaces GLP-1 driven growth for Hims, and peptides are emerging as one of the clearest candidates so far.
-
Entertainment1 week agoQueen Elizabeth II emotional message for Archie, Lilibet sparks speculation
-
Tech1 week agoAzure customers up in arms over ‘full’ UK South region | Computer Weekly
-
Tech1 week agoAs the Strait of Hormuz Reopens, Global Shipping Will Take Months to Recover
-
Fashion1 week agoCII submits 20-pt agenda to Indian govt to back firms hit by Iran war
-
Tech1 week agoThis AI Button Wearable From Ex-Apple Engineers Looks Like an iPod Shuffle
-
Politics7 days agoIndian airlines hit hardest after Dubai limits foreign flights until May 31
-
Entertainment4 days agoPalace left in shock as Prince William cancels grand ceremony
-
Politics6 days agoChinese, Taiwanese will unite, Xi tells Taiwan opposition leader
